Frexalimab (SAR441344) as a potential multiautoimmune disorder tackling mAB targeting the CD40-CD40L pathway undergoing clinical trials: a reviewTehreem Fatima, Aymar Akilimali, Faiza Fatima et al.|Annals of Medicine and Surgery|2024Cited by 7